Joanna Schwartz, Pharm.D., BCOP

Assistant Professor
Department of Pharmacy Practice, Vermont Campus 
Tel: (802) 735-2625
E-mail: joanna.schwartz@acphs.edu

Education:

• Board Certified Oncology Pharmacist (BCOP)
  
  PGY1 residency and Oncology residency at the Hospital of the University of Pennsylvania, Philadelphia, PA
  
  Pharm.D., Drake University College of Pharmacy, Des Moines, IA

Practice Site:

• Fletcher Allen Healthcare/University of Vermont Medical School, Vermont Cancer Center (Ambulatory Care Chemotherapy Infusion Clinic), Burlington, VT. 

Current Research Study:

• Randomized, blinded study of loratadine (Claritan) for the prevention and treatment of pegfilgrastim-induced bone pain.

Selected Publications:

• Pharmacy Practice, Vol 8(11).  J Oncol Pharm Pract 1078155211409473, first published on August 1, 2011 as doi:10.1177/1078155211409473
  
  Schwartz, J. Novel Targeted Agents for Metastatic Breast Cancer. The Oncology Pharmacist. Vol 4 (1). Feb 2011.
  
  Schwartz, J. New Treatments for Metastatic Breast Cancer. The Oncology Nurse. Vol 4 (1). Feb 2011.
  
  Schwartz, J. Non-anthracycline chemotherapy regimens for the adjuvant treatment of early stage breast cancers. Formulary, Newsletter Edition, November 2010.
  
  DS Dizon, A Stuckey, J Schwartz. Pegylated liposomal doxorubicin in recurrent serous carcinoma of the uterus. J Clin Oncol 2010; 27 (Suppl; abstr e16538).
  
  Schwartz J.Current combination chemotherapy regimens for metastatic breast cancer. American Journal of Health-System Pharmacy.Vol. 66, Issue 23_Supplement_6, S3-S8, 2009
  
  Schwartz J, Toste B, and Dizon D. Chemotherapy toxicity in gynecologic cancer patients with a BSA > 2 m2: The experience from the Program in Women’s Oncology/Brown Medical School. Gynecologic Oncology,.113; Vol 114, Iss 1, July 2009, p. 53-56.
  
  McCourt C, Young M, Schwartz, J, Young W, DiSilvestro P, Brard L, Tejada-Berges T, Bradley A, Dizon, D. Factors associated with response to taxanes as a later-line treatment of recurrent ovarian cancer. International Journal of Gynecologic Cancer.19(3):343-347, April 2009.
  
  Abellar R, Pepperell J, Greco D, Gundogan F, Kostanidov S, Schwartz J, Tantrahavi U, DePaepe M. Effects of Chemotherapy During Pregnancy on the Placenta. Pedia Devel Pathol. 2009 Mar 12(1):35 - 41.
  
  Dizon D, Schwartz J, Kemeny N. Hepatic Arterial Infusion (HAI) of chemotherapy for the treatment of colorectal cancer liver metastases. Surg Oncol Clin N Am. 2008 (17): 759 - 71.
  
  Schwartz, J, Bandera, C, Bradley A, Brard L, Legare R. Granai CO, Dizon, D. Does the Platinum-Free Interval Predict the Incidence or Severity of Hypersensitivity Reactions to Carboplatin? The Experience from Women and Infants’ Hospital. Gynecologic Oncology. 2007 (105): 81-83.
  
  Dizon D, Schwartz J, Rojan A, et al. Cross-Sensitivity Between Paclitaxel and Docetaxel in a Women's Cancers' Program. Gynecologic Oncology. 2006 Jan;100(1):149-151.
  
  Dizon D, Weitzen S, Rojan A, Schwartz J, et al. Two for Good Measure: Six versus Eight Cycles of Carboplatin and Paclitaxel as Adjuvant Treatment for Epithelial Ovarian Cancer. Gynecologic Oncology. 2006. Jan:100(2): 417-421.
  
  Gordinier M, Dizon D, Fleming E, Weitzen S, Schwartz J, et al. Elevated Body Mass Index Does Not Increase the Risk of Palmar-Plantar Erythrodysesthesia in Patients Receiving Pegylated Liposomal Doxorubicin. Gynecologic Oncology. 2006 (103): 72-74.
  
  Schwartz J, Domchek SM, Hwang WT, Fox K, et al. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Annals of Oncology. 2005 Feb;16(2):247-52.

Professional Organizations:

• President of the Vermont Society of Health-System Pharmacists (VTSHP) for 2011-2012

Faculty Advising:

• Faculty Advisor for the ACPHS-VT Campus Colleges Against Cancer and the Multicultural Club.